OrbusNeich Expands Portfolio to Treat Peripheral Disease

HONG KONG, May 24, 2016 /PRNewswire/ --

The innovator of COMBO™,the world's first dual therapy stent, introduces catheters for lower limb and AV fistula intervention 

OrbusNeich, a global company specializing in the provision of life-changing vascular solutions, has expanded its portfolio to include products to treat peripheral artery disease. The JADE™ and Scoreflex™ PTA balloons are the company's first entry devices for lower limb and arteriovenous (AV) fistula intervention.

An estimated 202 million* people worldwide are living with peripheral artery disease, a serious condition that can lead to amputations. This represents a large and growing patient population, resulting in a greater need for innovative endovascular devices.

Below-the-Knee (BTK) 

OrbusNeich's BTK portfolio includes the JADE non-compliant balloon, featuring a hybrid rapid-exchange/over-the-wire design for additional push and deliverability. This will be complemented with the Scoreflex PTA device, a dual wire balloon designed for focused force angioplasty which enables lesion optimization at lower pressures. Both devices will be 0.014" compatible and available in 150 cm working lengths.

Superficial Femoral Artery (SFA) 

Furthermore, OrbusNeich introduces an 0.018" Scoreflex PTA balloon for Superficial Femoral Artery treatment, available in 90 cm working lengths. This focused force angioplasty device has been designed to allow for balloon stability at larger diameters needed for treating the SFA.

Arteriovenous Fistula 

In addition to their lower limb intervention solutions, OrbusNeich will be offering a 40 cm working length Scoreflex PTA balloon for the treatment of patients on long-term dialysis with chronic restenosis of their AV fistula.  The focused force angioplasty technology is ideal in these resistant lesions where balloon stability and resolution of the stenosis at a lower pressure can be beneficial.

"Broadening our offering to include peripheral products is a natural progression for OrbusNeich," said B Wayne Johnson, President and Chief Operating Officer, OrbusNeich. "We have a strong reputation in designing balloons for treating highly complex coronary lesions and now we bring this technology to our dedicated peripheral devices to help physicians treat the difficult patient scenarios in endovascular disease. We believe our devices have the potential to make a real impact in patients who are living with peripheral artery disease".

OrbusNeich is a leader in coronary artery disease treatment with the innovative COMBO Dual Therapy Stent, the first dual therapy stent to accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days.

About OrbusNeich - Pioneers in life-changing technologies 

OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, Scoreflex™, Sapphire™ II, Sapphire™ II PRO and Sapphire™ II NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

* http://www.medpagetoday.com , Peripheral Artery Disease, 08.02.2013